Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

UFS scientists involved in groundbreaking research to protect rhino horns
2010-07-27

Pictured from the left are: Prof. Paul Grobler (UFS), Prof. Antoinette Kotze (NZG) and Ms. Karen Ehlers (UFS).
Photo: Supplied

Scientists at the University of the Free State (UFS) are involved in a research study that will help to trace the source of any southern white rhino product to a specific geographic location.

This is an initiative of the National Zoological Gardens of South Africa (NZG).

Prof. Paul Grobler, who is heading the project in the Department of Genetics at the UFS, said that the research might even allow the identification of the individual animal from which a product was derived. This would allow law enforcement agencies not only to determine with certainty whether rhino horn, traded illegally on the international black market, had its origin in South Africa, but also from which region of South Africa the product came.

This additional knowledge is expected to have a major impact on the illicit trade in rhino horn and provide a potent legal club to get at rhino horn smugglers and traders.

The full research team consists of Prof. Grobler; Christiaan Labuschagne, a Ph.D. student at the UFS; Prof. Antoinette Kotze from the NZG, who is also an affiliated professor at the UFS; and Dr Desire Dalton, also from the NZG.

The team’s research involves the identification of small differences in the genetic code among white rhino populations in different regions of South Africa. The genetic code of every species is unique, and is composed of a sequence of the four nucleotide bases G, A, T and C that are inherited from one generation to the next. When one nucleotide base is changed or mutated in an individual, this mutated base is also inherited by the individual's progeny.

If, after many generations, this changed base is present in at least 1% of the individuals of a group, it is described as a single nucleotide polymorphism (SNP), pronounced "snip". Breeding populations that are geographically and reproductively isolated often contain different patterns of such SNPs, which act as a unique genetic signature for each population.

The team is assembling a detailed list of all SNPs found in white rhinos from different regions in South Africa. The work is done in collaboration with the Pretoria-based company, Inqaba Biotech, who is performing the nucleotide sequencing that is required for the identification of the SNPs.

Financial support for the project is provided by the Advanced Biomolecular Research cluster at the UFS.

The southern white rhino was once thought to be extinct, but in a conservation success story the species was boosted from an initial population of about 100 individuals located in KwaZulu-Natal at the end of the 19th century, to the present population of about 15 000 individuals. The southern white rhino is still, however, listed as “near threatened” by the World Wildlife Fund (WWF).

Media Release:
Mangaliso Radebe
Assistant Director: Media Liaison
Tel: 051 401 2828
Cell: 078 460 3320
E-mail: radebemt@ufs.ac.za 
27 July 2010



 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept